Acetyl-L-carnitine

Acetyl-L-carnitine is filed as Amino acid derivative. The sections below restate public label fields stored for this profile.

Class
Amino acid derivative
Route
INTRAVENOUS
Dosage forms
HOW SUPPLIED PREMASOL 10% - sulfite-free (amino acids) injection is supplied in VIAFLEX plastic Pharmacy Bulk Package containers in the following sizes and concentrations: 500 mL 1000 mL 2000 mL 10% 2B0012 2B0009 2B0010 NDC 0338-1130-03 NDC 0338-1130-04 NDC 0338-1130-06 Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Protect from freezing. It is recommended the product be stored at room temperature (25°C/77°F). Brief exposure up to 40°C/104°F does not adversely affect the product. Protect from light until immediately prior to use. Do not remove container from overpouch until ready to use. Do not use if overpouch has been previously opened or damaged.
Manufacturer
Baxter Healthcare Company
Boxed warning
Yes

Approved uses

INDICATIONS AND USAGE PREMASOL 10% injection is indicated for the nutritional support of infants (including those of low birth weight) and young children requiring TPN via either central or peripheral infusion routes. Parenteral nutrition with PREMASOL 10% injection is indicated to prevent nitrogen and weight loss or treat negative nitrogen balance in infants and young children where: (1) the alimentary tract, by the oral, gastrostomy, or jejunostomy route, cannot or should not be used, or adequate protein intake is not feasible by these routes; (2) gastrointestinal absorption of protein is impaired; or (3) protein requirements are substantially increased as with extensive burns. Dosage, route of administration, and concomitant infusion of non-protein calories are dependent on various factors, such as nutritional and metabolic status of the patient, anticipated duration of parenteral nutritional support, and vein tolerance (see DOSAGE AND ADMINISTRATION ). Central Venous Nutrition Central venous infusion should be considered when amino acid solutions are to be admixed with hypertonic dextrose to promote protein synthesis in hypercatabolic or severely depleted infants, or those requiring long-term parenteral nutrition. Peripheral Parenteral Nutrition For moderately catabolic or depleted patients in whom the central venous route is not indicated, diluted amino acid solutions mixed with 5-10% dextrose solutions may be infused by peripheral vein, supplemented, if desired, with fat emulsion.

How it works

CLINICAL PHARMACOLOGY PREMASOL 10% injection provides a mixture of essential and nonessential amino acids as well as taurine and a soluble form of tyrosine, N-Acetyl-L-Tyrosine (NAT). This amino acid composition has been specifically formulated to provide a well tolerated nitrogen source for nutritional support and therapy for infants and young children. When administered in conjunction with cysteine hydrochloride, 10% Amino Acid Injections result in the normalization of the plasma amino acid concentrations to a profile consistent with that of a breast-fed infant. The rationale for a 10% amino acids injection is based on the observation of inadequate levels of essential amino acids in the plasma of infants receiving total parenteral nutrition (TPN) using conventional amino acid solutions. These formulas were developed through the application of specific pharmacokinetic multiple regression analysis relating amino acid intake to the resulting plasma amino acid concentrations. Clinical studies in infants and young children who required TPN therapy showed that infusion of a 10% amino acids injection with a cysteine hydrochloride admixture resulted in a normalization of the plasma amino acid concentrations. In addition, weight gains, nitrogen balance, and serum protein concentrations were consistent with an improving nutritional status. When infused with hypertonic dextrose as a calorie source, supplemented with cysteine hydrochloride, electrolytes, vitamins, and minerals, PREMASOL 10% injection provides total parenteral nutrition in infants and young children, with the exception of essential fatty acids. It is thought that the acetate from lysine acetate and acetic acid, under the conditions of parenteral nutrition, does not impact net acid-base balance when renal and respiratory functions are normal. Clinical evidence seems to support this thinking; however, confirmatory experimental evidence is not available. The amount of chloride present in PREMASOL 10% injection is not of clinical significance. The addition of cysteine hydrochloride will contribute to the chloride load. The electrolyte content of any additives that are introduced should be carefully considered and included in total input computations.

Boxed warning

Pharmacy Bulk Package Not for Direct Infusion

Warnings and precautions

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Contraindications

CONTRAINDICATIONS PREMASOL 10% injection is contraindicated in patients with untreated anuria, hepatic coma, inborn errors of amino acid metabolism, including those involving branched chain amino acid metabolism such as maple syrup urine disease and isovaleric acidemia, or hypersensitivity to one or more amino acids present in the solution.

Adverse reactions

ADVERSE REACTIONS See WARNINGS and Special Precautions for Central Venous Nutrition . Reactions reported in clinical studies as a result of infusion of the parenteral fluid were water weight gain, edema, increase in BUN, and mild acidosis. Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation, and hypervolemia. Local reaction at the infusion site, consisting of a warm sensation, erythema, phlebitis and thrombosis, have been reported with peripheral amino acid infusions, especially if other substances are also administered through the same site. If electrolyte supplementation is required during peripheral infusion, it is recommended that additives be administered throughout the day in order to avoid possible venous irritation. Irritating additive medications may require injection at another site and should not be added directly to the amino acid infusate. Symptoms may result from an excess or deficit of one or more of the ions present in the solution; therefore, frequent monitoring of electrolyte levels is essential. Phosphorus deficiency may lead to impaired tissue oxygenation and acute hemolytic anemia. Relative to calcium, excessive phosphorus intake can precipitate hypocalcemia with cramps, tetany and muscular hyperexcitability. If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary.

Dosage and administration

DIRECTIONS: Take one to two softgels daily, or as directed by your physician. For children under 12 years of age, consult your physician.

Common questions

What is Acetyl-L-carnitine approved to treat?

According to its FDA label, Acetyl-L-carnitine is approved for: INDICATIONS AND USAGE PREMASOL 10% injection is indicated for the nutritional support of infants (including those of low birth weight) and young children requiring TPN via either central or peripheral infusion routes. Parenteral nutrition with PREMASOL 10% injection is indicated… For medical advice, please talk to your prescriber or pharmacist.

What class of drug is Acetyl-L-carnitine?

Acetyl-L-carnitine belongs to the Amino acid derivative class of medications.

What form does Acetyl-L-carnitine come in?

The FDA label lists Acetyl-L-carnitine as: HOW SUPPLIED PREMASOL 10% - sulfite-free (amino acids) injection is supplied in VIAFLEX plastic Pharmacy Bulk Package containers in the following sizes and concentrations: 500 mL 1000 mL 2000 mL 10% 2B0012 2B0009 2B0010 NDC 0338-1130-03 NDC 0338-1130-04 NDC 0338-1130-06 Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Protect from freezing. It is recommended the product be stored at room temperature (25°C/77°F). Brief exposure up to 40°C/104°F does not adversely affect the product. Protect from light until immediately prior to use. Do not remove container from overpouch until ready to use. Do not use if overpouch has been previously opened or damaged.; intravenous route. Available strengths and packaging vary by manufacturer.

Does Acetyl-L-carnitine have a Boxed Warning?

Yes. The FDA label for Acetyl-L-carnitine carries a Boxed Warning. Excerpt: "Pharmacy Bulk Package Not for Direct Infusion" See the full FDA label for the complete warning. For medical advice, please talk to your prescriber or pharmacist.

Is Acetyl-L-carnitine currently under recall?

The FDA Enforcement Report does not show an active/ongoing recall for Acetyl-L-carnitine in our latest ingest. Recall data can change daily — verify at FDA.gov.

When was Acetyl-L-carnitine approved by the FDA?

The FDA record lists the approval date for Acetyl-L-carnitine as 2003-06-19.

Who makes Acetyl-L-carnitine?

The FDA label lists Baxter Healthcare Company as a labeler/manufacturer of Acetyl-L-carnitine. Multiple firms may market generics of the same molecule.

On this site

Related medications in this class or category

Loading full data from Know Your Drugs Institute…